Skip to main content
Clinical Trials/NL-OMON50334
NL-OMON50334
Completed
Phase 3

A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC). - TheraSphere® in Unresectable Hepatocellular Carcinoma (HCC). STOP-HCC

Biocompatibles UK Ltd.0 sites38 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
hepatocellular carcinoma
Sponsor
Biocompatibles UK Ltd.
Enrollment
38
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Must have signed informed consent prior to any study\-related evaluation
  • 2\. Must be male or female patients over 18 years of age
  • 3\. Must have unresectable HCC confirmed by histology or by non\-invasive AASLD10
  • 4\. Must have measurable disease defined as at least one uni\-dimensional
  • measurable lesion by CT
  • or MRI (according to RECIST 1\.1\)
  • 5\. Must have a Child Pugh score \<\= 7 points
  • 6\. Must have an ECOG Performance Status score of \<\= 1
  • 7\. Must have a Life expectancy of 12 weeks or more
  • 8\. Must have be eligible to receive SOC sorafenib

Exclusion Criteria

  • 16\. Must not have main PVT (branch portal vein thrombosis is permissible).
  • 17\. Must not be eligible for curative treatment (e.g ablation or
  • transplantation)
  • 18\. Must not have a history of previous or concurrent cancer other than HCC
  • unless treated curatively 5 or more years prior to entry
  • 19\. Must not have confirmed presence of extra\-hepatic disease with the
  • exception of lung nodules
  • and mesenteric or portal lymph nodes \<\= 2\.0 cm each
  • 20\. Must not be at risk of hepatic or renal failure
  • 21\. Must not have tumor replacement \>70% of total liver volume based on visual

Outcomes

Primary Outcomes

Not specified

Similar Trials